Clinical-Microbiomics, CosmosID, DNASense, and MS-Omics have merged to form Cmbio. Please visit our new site cmbio.ioVisit cmbio.io
 

Blog

bt_bb_section_bottom_section_coverage_image

Advancements in biological and biomedical research are fueled by the analysis of vast, complex, integrated datasets, made possible through large-scale computational resources.   While bioinformatics has revolutionized our understanding of diseases such as cancer or COVID-19, there are costs associated with the computing requirements. On one hand, computational power requires financial process, but it may...

The field of microbiome-based therapeutics is flourishing. The recent approval of Seres Therapeutics’ drug, Vowst, against C. difficile infections has spearheaded the interest in microbiome-based therapeutics.    The recent development of microbiome-based therapeutics may have contributed to a rising trend of reclassifying microbiome probiotics as pharmaceuticals. The European Union (EU) is witnessing significant progress in...

The gut microbiome has clear implications for health and disease. Recent evidence of this comes from a US FDA vote for approval of the microbiome-based drug RBX2660, created by Rebiotix Inc, A Ferring Company, to treat potentially deadly bacterial infections with Clostridium difficile (Cdiff). Cdiff is a common gut bacteria that may cause severe diarrhea...